908 Devices (NASDAQ:MASS) Receives Sell (E+) Rating from Weiss Ratings

908 Devices (NASDAQ:MASS - Get Free Report)'s stock had its "sell (e+)" rating reissued by stock analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

MASS has been the topic of several other reports. Stifel Nicolaus dropped their price target on 908 Devices from $17.00 to $6.00 and set a "buy" rating on the stock in a research report on Wednesday, November 13th. Stephens reiterated an "overweight" rating and issued a $6.00 target price on shares of 908 Devices in a report on Wednesday, January 15th. Leerink Partners reissued a "market perform" rating and issued a $4.00 price target (down from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th. Finally, Leerink Partnrs downgraded shares of 908 Devices from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $5.33.

908 Devices Stock Up 14.6 %

Shares of 908 Devices stock traded up $0.44 during trading on Friday, hitting $3.46. The stock had a trading volume of 1,400,280 shares, compared to its average volume of 3,811,955. 908 Devices has a 1 year low of $1.81 and a 1 year high of $7.56. The stock has a 50 day simple moving average of $2.54 and a 200 day simple moving average of $2.91. The company has a market capitalization of $120.49 million, a PE ratio of -1.95 and a beta of 0.99.

Remove Ads

Institutional Investors Weigh In On 908 Devices

Large investors have recently bought and sold shares of the business. Prescott Group Capital Management L.L.C. acquired a new stake in shares of 908 Devices in the fourth quarter worth about $330,000. Needham Investment Management LLC raised its stake in shares of 908 Devices by 100.0% in the 4th quarter. Needham Investment Management LLC now owns 200,000 shares of the company's stock valued at $440,000 after acquiring an additional 100,000 shares in the last quarter. AWM Investment Company Inc. lifted its holdings in 908 Devices by 6.3% in the 4th quarter. AWM Investment Company Inc. now owns 1,673,924 shares of the company's stock worth $3,683,000 after purchasing an additional 99,594 shares during the last quarter. Deutsche Bank AG boosted its position in 908 Devices by 1,159.4% during the fourth quarter. Deutsche Bank AG now owns 99,239 shares of the company's stock worth $218,000 after purchasing an additional 91,359 shares during the period. Finally, Bank of America Corp DE grew its holdings in 908 Devices by 190.9% during the fourth quarter. Bank of America Corp DE now owns 94,753 shares of the company's stock valued at $208,000 after purchasing an additional 62,179 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.